> GLP-1 agonists (such as Novo's Ozempic) are another example in healthcare. Despite their effectiveness, Pfizer rejected GLP-1s in the 1990s because they would eat into their other product lines. It took over a decade before another company, Novo, commercialized them.
Pretty sure this happens all the time those days. Big corps being happy with status quo, and not doing X until a small motivated competitor does.
Pretty sure this happens all the time those days. Big corps being happy with status quo, and not doing X until a small motivated competitor does.